AstraZeneca’s key lung cancer treatment fails main goal in late-stage trial

Share this post

AstraZeneca’s combination of two immunotherapy drugs did not meet the main goal in a closely watched late-stage study for certain type of stage IV lung cancer, the company said on Friday.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply